Neophyr (Nitric Oxide)

Nitric Oxide, the active ingredient in Neophyr, is a nitric oxide donor presented as a medical gas for inhalation use. It delivers selective pulmonary vasodilation, helping to lower pulmonary arterial pressure in patients with pulmonary hypertension.

GNH USA supplies Neophyr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable sourcing for clinical and institutional customers across multiple regions. Our distribution network ensures timely delivery and regulatory support for each order.

Neophyr is used to manage conditions involving elevated pulmonary vascular resistance.

Pulmonary arterial hypertension: lowers pulmonary arterial pressure, enhancing oxygen delivery and exercise tolerance. Chronic thromboembolic pulmonary hypertension: promotes selective vasodilation of pulmonary vessels, aiding symptom relief. Right ventricular overload due to pulmonary hypertension: decreases afterload on the right heart, supporting cardiac function.

Adverse reactions may occur with inhaled nitric oxide therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Flushing of the skin. - Nausea or mild gastrointestinal upset. - Cough or throat irritation. - Transient systemic hypotension.

Serious or Rare Side Effects: - Methemoglobinemia: elevated methemoglobin levels causing reduced oxygen delivery. - Rebound pulmonary hypertension upon abrupt discontinuation. - Severe systemic hypotension leading to syncope. - Bleeding complications in patients on anticoagulants. - Pulmonary edema in susceptible individuals.

Neophyr requires careful clinical monitoring and adherence to safety guidelines.

Indication verification: confirm diagnosis of pulmonary hypertension before initiation. Monitoring: regularly assess pulmonary artery pressure, oxygenation, and methemoglobin levels. Contraindications: avoid use in patients with severe left ventricular dysfunction. Pregnancy: consider only if potential benefits outweigh risks. Drug interactions: be aware of additive vasodilatory effects with phosphodiesterase inhibitors. Store at ambient temperature (below 30°C): keep cylinder in original packaging, protect from direct sunlight and extreme heat.

Nitric Oxide therapy may interact with other agents affecting vascular tone.

Major Interactions (Avoid): - Sildenafil or other phosphodiesterase‑5 inhibitors: additive vasodilation causing profound hypotension. - Concurrent inhaled vasodilators (e.g., inhaled prostacyclin): risk of excessive pulmonary vasodilation. - Systemic nitroglycerin: synergistic hypotensive effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk due to vasodilatory changes. - Beta‑blockers: may blunt hemodynamic response to therapy. - Inhaled corticosteroids: generally safe, but monitor for respiratory irritation.